The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 25, Issue 5, 2014, Pages 1083-1093

  De Zeeuw, Dick ^a   Coll, Blai ^b   Andress, Dennis ^b   Brennan, John J ^b   Tang, Hui ^b   Houser, Mark ^b   Correa Rotter, Ricardo ^c   Kohan, Donald ^d   Heerspink, Hiddo J Lambers ^a   Makino, Hirofumi ^e   Perkovic, Vlado ^f   Pritchett, Yili ^g   Remuzzi, Giuseppe ^h   Tobe, Sheldon W ⁱ   Toto, Robert ^j   Viberti, Giancarlo ^k   Parving, Hans Henrik ^l  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ABBVIE INC   (United States)

^c Nutrition Institute ^*  (Mexico)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^e OKAYAMA UNIVERSITY   (Japan)

^f UNIVERSITY OF SYDNEY   (Australia)

^g ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^h MARIO NEGRI INST PHARMACOL RES   (Italy)

ⁱ SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l Rigshospitalet   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ATRASENTAN; BRAIN NATRIURETIC PEPTIDE; CREATININE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SERUM ALBUMIN; TRIACYLGLYCEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; LIPID; PYRROLIDINE DERIVATIVE;

ACUTE APPENDICITIS; ADULT; AGED; ALBUMINURIA; ANEMIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FACE EDEMA; FATIGUE; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; INTENTION TO TREAT ANALYSIS; KIDNEY FUNCTION; LOW DRUG DOSE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOSE OBSTRUCTION; PARALLEL DESIGN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THYROID CANCER; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; BLOOD; BLOOD PRESSURE; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; KIDNEY FUNCTION TEST;

AGED; ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIN-1; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; LIPIDS; MALE; MIDDLE AGED; PYRROLIDINES;

EID: 84906540059     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013080830     Document Type: Article

References (20)

1. Heerspink HJ, de Zeeuw D: The kidney in type 2 diabetes therapy. Rev Diabet Stud 8: 392-402, 2011
2. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, CooperME,MitchWE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 65: 2309-2320, 2004
3. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, DeFerrari G, Drury P, Locatelli F,Wiegmann TB, Lewis EJ: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45: 281-287, 2005
4. Cravedi P, Ruggenenti P, Remuzzi G: Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 8: 301-306, 2012
5. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J Nephrol 21: 566-569, 2008
6. Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, Weber MA, McQueen M, Koon T, Yusuf S; ONTARGET Investigators: Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 22: 1353-1364, 2011
7. Kohan DE: Endothelin, hypertension and chronic kidney disease: New insights. Curr Opin Nephrol Hypertens 19: 134-139, 2010
8. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; ASCEND Study Group: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21: 527-535, 2010
9. Ko KohanDE, PollockDM: Endothelin antagonists for diabetic and nondiabetic chronic kidney disease. Br J Clin Pharmacol 76: 573-579, 2013
10. Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F, Rossi M, Conti S, Rottoli D, Longaretti L, Remuzzi A, Remuzzi G, Benigni A: Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 297: F1448-F1456, 2009
11. Simonson MS, Ismail-Beigi F: Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. J Biol Chem286: 11003-11008, 2011
12. Wenzel RR, Littke T, Kuranoff S, Jürgens C, Bruck H, Ritz E, Philipp T, Mitchell A; SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators: Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 20: 655-664, 2009
13. GalièN, HoeperMM, Gibbs JS, Simonneau G: Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Respir J 37: 475-476, 2011
14. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B,Meier PJ: The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69: 223-231, 2001
15. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, Gehrke LJ, Hernandez L, Magnuson SR, Marsh KC, Novosad EI, Von Geldern TW, Wessale JL, Winn M,Wu-Wong JR: Pharmacological characterization of A-127722: An orally active and highly potent ETAselective receptor antagonist. J Pharmacol Exp Ther 276: 473-481, 1996
16. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL: Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22: 763-772, 2011
17. AbbVie: A prospective, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of atrasentan, including thoracic bioimpedance, in type 2 diabetic subjects with nephropathy. Available at: http://clinicaltrials.gov/ct2/show/NCT01399580?term=atrasentan+and+bioimpedance&rank=1. Accessed October 10, 2013
18. de Zeeuw D, Gansevoort RT, Dullaart RP, de Jong PE: Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. J Hypertens Suppl 13: S53-S58, 1995
19. Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S, Goddard J, Webb DJ: Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 57: 772-779, 2011
20. AbbVie: Randomized, multicountry, multicenter, double-blind, parallel, placebo-controlled study of the effects of atrasentan on renal outcomes in subjects with type 2 diabetes and nephropathy SONAR: Study of Diabetic Nephropathy with Atrasentan. Available at: http://clinicaltrials.gov/ct2/show/NCT01858532?term=sonar&rank=1. Accessed October 10, 2013